Related Experiment Video
Updated: Mar 20, 2026
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Something Old, Something New, Something Borrowed, Something Fused: Novel EGFR Rearrangements in Lung Adenocarcinomas
1Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Weill Cornell Medical College, New York, New York. paikp@mskcc.org.
Abstract:
Mutations in EGFR stand as the archetype for somatic alterations that lead to oncogene addiction and that predict for response to targeted therapies. In this issue of Cancer Discovery, Konduri and colleagues report on a pair of novel oncogenic and actionable EGFR fusion events in a series of patients with lung adenocarcinomas, casting new light on this model gene. Cancer Discov; 6(6); 574-5. ©2016 AACRSee related article by Konduri et al., p. 601.
Insights
Researchers identified novel EGFR gene fusions in lung cancer patients. These actionable mutations offer new targets for personalized cancer therapy, advancing oncogene addiction research.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Epidermal growth factor receptor (EGFR) mutations are key drivers of oncogene addiction in cancer.
- EGFR alterations predict patient response to targeted therapies.
- Understanding novel EGFR alterations is crucial for advancing precision medicine.
Purpose of the Study:
- To identify and characterize novel oncogenic EGFR fusion events in lung adenocarcinomas.
- To investigate the therapeutic potential of these newly discovered EGFR fusions.
Main Methods:
- Genomic analysis of patient tumor samples.
- Identification of EGFR gene rearrangements.
- Functional characterization of identified EGFR fusion proteins.
Main Results:
- Discovery of two distinct, novel EGFR fusion events in lung adenocarcinoma.
- These fusions were found to be oncogenic and actionable.
- The findings expand the landscape of known EGFR alterations.
Conclusions:
- Novel EGFR fusions represent a new class of driver mutations in lung cancer.
- These actionable fusions provide new therapeutic targets for lung adenocarcinoma patients.
- This research deepens the understanding of EGFR's role in oncogenesis.
More Related Videos
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
